Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Clinical and Socioeconomic Factors Influence Treatment Decisions in Graves’ Disease
source: Annals of Surgical Oncology
year: 2015
authors: Elfenbein DM, Schneider DF, Havlena J, Chen H, Sippel RS
summary/abstract:Background:
Definitive treatment of Graves’ disease includes radioactive iodine (RAI) and thyroidectomy, but utilization varies. We hypothesize that, in addition to clinical reasons, there are socioeconomic factors that influence whether a patient undergoes thyroidectomy or RAI.
Methods:
Patients treated for Graves’ disease between August 2007 and September 2013 at our university hospital were included. A comparative analysis of clinical and socioeconomic factors was completed.
Results:
Of 427 patients, 300 (70 %) underwent RAI, whereas 127 (30 %) underwent surgery. Multiple factors were associated with surgery: younger age (mean 36 vs. 41 years, p < 0.01), female gender (33 vs. 19 % males, p = 0.01), black race (56 vs. 28 % nonblack, p < 0.01), Medicaid or uninsured (43 vs. 27 % private insurance or Medicare, p < 0.01), ophthalmopathy (38 vs. 26 %, p < 0.01), goiter (35 vs. 23 %, p < 0.01), and lowest quartile of median household income (38 vs. 27 % upper three quartiles, p = 0.03). Thyroidectomy increased annually, with 52 % undergoing surgery during the final year (p < 0.01). Adjusting for confounding, younger age (odds ratio [OR] 1.04; 95 % confidence interval [CI] 1.02, 1.05), female gender (OR 2.06; 95 % CI 1.06, 4.01), ophthalmopathy (OR 2.35; 95 % CI 1.40, 3.96), and later year of treatment (OR 1.66; 95 % CI 1.41, 1.95) remained significantly associated with surgery.
Conclusions:
Surgery has now become the primary treatment modality of choice for Graves’ disease at our institution. Clinical factors are the main drivers behind treatment choice, but patients with lower SES are more likely to have clinical features best treated with surgery, underlying the importance of improving access to quality surgical care for all patients.
DOI: 10.1245/s10434-014-4095-6
read more full text
Related Content
-
Nicholas Robert Mahoney, MDNicholas Robert Mahoney is an Associate ...
-
TSH-Receptor Autoimmunity in Graves’ Disease After Therapy With Anti-Thyroid Drugs, Surgery, or Radioiodine: A...Introduction: Autoimmunity against the ...
-
Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With HyperthyroidismImportance Radioactive iodine (RAI) h...
-
Weight Gain After Treatment of Graves’ Disease in ChildrenObjective: The frequency of and risk fa...
-
Treatment Options for Thyroid Eye or Graves’ Disease at Ohio Statehttps://www.youtube.com/watch?v=2vcbs9hu...
-
Risk Factors For Developing Thyroid-Associated Ophthalmopathy Among Individuals with Graves’ DiseaseImportance: Thyroid-associated ophthalm...
-
Thomas E. Johnson, MDThomas E Johnson, MD is a Professor of C...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.